Aduro BioTech Inc. said it plans to lay off 51 employees — or about 59% of its workforce — as part of a corporate restructuring.
The Berkeley, Calif.-based biopharmaceutical company also said it plans to minimize its corporate facilities footprint and shut down its European headquarters in Oss, The Netherlands, by the end of the third quarter.
Aduro said the restructuring is expected to extend the company's operating capital.
The company said the planned changes were determined following an analysis of its product candidates targeting the intracellular stimulator of interferon genes, or STING, and a proliferation-inducing ligand — both proteins found in the human body. STING can influence the immune response associated with various autoimmune diseases, a condition where the body's immune system attacks healthy tissue.
The company also conducted an analysis of its cGAS-STING collaboration with Eli Lilly and Co.
"We are creating a more streamlined organization by focusing on generating clinical data and identifying candidates for the cGAS program to bring forward into development," the company said in a news release.